APOLIPOPROTEIN-E PREVENTS THE PROGRESSION OF ATHEROSCLEROSIS IN WATANABE HERITABLE HYPERLIPIDEMIC RABBITS

被引:83
|
作者
YAMADA, N
INOUE, I
KAWAMURA, M
HARADA, K
WATANABE, Y
SHIMANO, H
GOTODA, T
SHIMADA, M
KOHZAKI, K
TSUKADA, T
SHIOMI, M
WATANABE, Y
YAZAKI, Y
机构
[1] SANRAKU HOSP,TOKYO,JAPAN
[2] KOBE UNIV,SCH MED,INST EXPTL ANIM,KOBE 650,JAPAN
来源
JOURNAL OF CLINICAL INVESTIGATION | 1992年 / 89卷 / 02期
关键词
APOLIPOPROTEIN-E; ATHEROSCLEROSIS; WATANABE HERITABLE HYPERLIPIDEMIC RABBIT; LOW DENSITY LIPOPROTEIN RECEPTOR; CHOLESTEROL;
D O I
10.1172/JCI115639
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Apo E plays an important role in plasma lipoprotein metabolism through its high affinity binding to cell surface LDL receptor. In the present study, we studied the effects of apo E on the atherogenic process in Watanabe heritable hyperlipidemic rabbits which are deficient in LDL receptor and an animal model for familial hypercholesterolemia. We isolated apo E from plasma of 1% cholesterol-fed rabbits and administered 10 mg of purified apo E intravenously into five Watanabe heritable hyperlipidemic rabbits three times a week from their age of 2.5 months to 11 months for 8.5 months. After sustained administration of apo E, we found a significant reduction in the accumulation of cholesterol ester in aortae (1.55 +/- 0.07 mg/g tissue) as compared to control rabbits (4.32 +/- 0.61 mg/g tissue). Supporting this, the percentage of the surface area of the aorta with macroscopic plaque was remarkably decreased in apo E-treated animals (18.8 +/- 5.1% vs. 38.8 +/- 8.0% in control). Thus, apo E definitely prevented the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
引用
收藏
页码:706 / 711
页数:6
相关论文
共 50 条
  • [31] Effect of macrophage colony stimulating factor on the advanced atherosclerosis in watanabe heritable hyperlipidemic rabbits
    Watanabe, Y
    Inaba, T
    Shimano, H
    Gotoda, T
    Kawamura, M
    Shiomi, M
    Yazaki, Y
    Yamada, N
    HORMONE AND METABOLIC RESEARCH, 1997, 29 (10) : 507 - 509
  • [32] CHOLESTEROL-FED HETEROZYGOUS WATANABE HERITABLE HYPERLIPIDEMIC RABBITS - A NEW MODEL FOR ATHEROSCLEROSIS
    ATKINSON, JB
    HOOVER, RL
    BERRY, KK
    SWIFT, LL
    ATHEROSCLEROSIS, 1989, 78 (2-3) : 123 - 136
  • [33] THE EFFECTS OF PROBUCOL ON THE PROGRESSION OF ATHEROSCLEROSIS IN MATURE WATANABE HERITABLE HYPERLIPEMIC RABBITS
    DAUGHERTY, A
    ZWEIFEL, BS
    SCHONFELD, G
    BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (01) : 1013 - 1018
  • [34] THE DISTRIBUTION OF ELEMENTS IN THE TISSUES OF WATANABE HERITABLE HYPERLIPIDEMIC RABBITS
    ALLAIN, P
    KRARI, N
    CHALEIL, D
    BALANANT, Y
    BLED, F
    GIRAULT, M
    BIOLOGICAL TRACE ELEMENT RESEARCH, 1989, 19 (03) : 153 - 160
  • [35] Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits
    Gupta, H
    White, CR
    Handattu, S
    Garber, DW
    Datta, G
    Chaddha, M
    Dai, LJ
    Gianturco, SH
    Bradley, WA
    Anantharamaiah, GM
    CIRCULATION, 2005, 111 (23) : 3112 - 3118
  • [36] TRANDOLAPRIL INHIBITS ATHEROSCLEROSIS IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT
    CHOBANIAN, AV
    HAUDENSCHILD, CC
    NICKERSON, C
    HOPE, S
    HYPERTENSION, 1992, 20 (04) : 473 - 477
  • [37] Cholesterol lowering and anti-oxidant actions of an apolipoprotein E mimetic peptide in watanabe heritable hyperlipidemic (WHHL) rabbits
    White, CR
    Gupta, H
    Dai, LJ
    Garber, D
    Datta, G
    Anantharamiah, GM
    FREE RADICAL BIOLOGY AND MEDICINE, 2003, 35 : S178 - S179
  • [38] VASCULAR REACTIVITY DURING THE PROGRESSION OF ATHEROSCLEROTIC PLAQUE - A STUDY IN WATANABE HERITABLE HYPERLIPIDEMIC RABBITS
    KOLODGIE, FD
    VIRMANI, R
    RICE, HE
    MERGNER, WJ
    CIRCULATION RESEARCH, 1990, 66 (04) : 1112 - 1126
  • [40] Dietary soy supplement reduces aortic atherosclerosis in ovariectomized Watanabe heritable hyperlipidemic (WHHL) rabbits
    Mortensen, A
    Breinholt, V
    Frandsen, H
    Lund, C
    Ottesen, B
    Larsen, JJ
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 276 - 276